samedan logo

home > news > detailed info

Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT

Coave Therapeutics

Paris, France, 4th May 2022 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announced that research on its AAV-Ligand Conjugates platform (ALIGATER) will be presented at the 2022 American Society of Cell & Gene Therapy (ASCGT) meeting, which will be held virtually and in person in Washington, D.C., 16 to 19 May.

The poster presentation entitled ‘Chemically engineered AAV vectors to improve biodistribution and gene transfer to the central nervous system’ will highlight important pre-clinical data about the company’s proprietary ALIGATER platform, showing it can transform standard AAVs into more potent vectors to treat diseases that affect large and/or deep structures of the brain.

Poster details at the ASGCT 25th Annual Meeting

• Abstract Title: Chemically engineered AAV vectors to improve biodistribution and gene transfer to the central nervous system
• Abstract Number: 994 / Poster Board Number: W-120
• Poster Session: Synthetic/Molecular Conjugates and Physical Methods for Delivery II
• Room: Hall D
• Date & Time: Wednesday 18 May at 17:30 ET
• Presenter: Gaelle Lefevre, Head of Discovery Sciences at Coave Therapeutics
email 63bis avenue Ledru Rolin 75012 Paris
Print this page
Send to a friend
News and Press Releases

Clinigen expands US site capacity in response to growing demand for Clinical Supplies Management services

Clinigen Limited, the global pharmaceutical services company, announces it has nearly doubled its US site capacity to better service large-scale clinical trials.
More info >>

White Papers

Sterile Vials Made of Tubular Glass

Gerresheimer AG

Gx® RTF vials powered by Ompi EZ-fill® enhance flexibility by facilitating packaging needs from clinical stage to industrialization with the common goal to minimize customer product risks and optimize total cost of ownership. Gerresheimer combines the competencies in converting glass tubes to serum/ injection vials and ready-to-fill processing for our pharma and biotech customers.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement